Table 4. Multivariate analysis of prognostic factors in 594 LA NPC patients.

Endpoint	Variate	Category	HR	95% CI	P-value
OS	NAC cycle	2 cycles vs. 3 to 4 cycles	0.695	0.323–1.498	0.353
	Age	<60 vs. ≥60 years	0.451	0.209–0.973	0.042
	N stage*	N0-N1 vs. N2-N3	0.272	0.105–0.707	0.008
PFS	NAC cycle	2 cycles vs. 3 to 4 cycles	0.585	0.344–0.997	0.049
	N stage*	N0-N1 vs. N2-N3	0.483	0.280-0.834	0.009
LRRFS	NAC cycle	2 cycles vs. 3 to 4 cycles	0.820	0.459-1.532	0.535
DMFS	NAC cycle	2 cycles vs. 3 to 4 cycles	0.499	0.258–0.964	0.038
	N stage*	N0-N1 vs. N2-N3	0.239	0.101–0.565	0.001

OS, overall survival; PFS, progression-free survival; LRRFS, locoregional recurrence-free survival; DMFS, distant metastasis-free survival; NAC, neoadjuvant chemotherapy.

^*The 7th AJCC/UICC staging system.